Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

ClinicalTrials.gov ID: NCT00457392

Public ClinicalTrials.gov record NCT00457392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 12:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib

Study identification

NCT ID
NCT00457392
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
960 participants

Conditions and interventions

Interventions

  • erlotinib Drug
  • placebo Drug
  • sunitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2007
Primary completion
Jun 30, 2010
Completion
Nov 30, 2012
Last update posted
Oct 28, 2013

2007 – 2012

United States locations

U.S. sites
63
U.S. states
24
U.S. cities
56
Facility City State ZIP Site status
Pfizer Investigational Site Florence Alabama 35630
Pfizer Investigational Site Muscle Shoals Alabama 35661
Pfizer Investigational Site Scottsdale Arizona 85258
Pfizer Investigational Site Hot Springs Arkansas 71913
Pfizer Investigational Site Antioch California 94531
Pfizer Investigational Site Burbank California 91505-4866
Pfizer Investigational Site Downey California 90241
Pfizer Investigational Site Fresno California 93720
Pfizer Investigational Site La Jolla California 92037
Pfizer Investigational Site La Jolla California 92093-0987
Pfizer Investigational Site Montebello California 90640
Pfizer Investigational Site Pleasant Hill California 94523
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Leandro California 94578
Pfizer Investigational Site Whittier California 90606
Pfizer Investigational Site Fairfield Connecticut 06824
Pfizer Investigational Site Brooksville Florida 34613
Pfizer Investigational Site Cocoa Beach Florida 32931
Pfizer Investigational Site Fort Lauderdale Florida 33308
Pfizer Investigational Site Merritt Island Florida 32952
Pfizer Investigational Site Rockledge Florida 32955
Pfizer Investigational Site Titusville Florida 32796
Pfizer Investigational Site Athens Georgia 30607
Pfizer Investigational Site Aurora Illinois 60504
Pfizer Investigational Site Goshen Indiana 46526
Pfizer Investigational Site Indianapolis Indiana 46260-2082
Pfizer Investigational Site Council Bluffs Iowa 51503
Pfizer Investigational Site Baton Rouge Louisiana 70809
Pfizer Investigational Site Lafayette Louisiana 70503
Pfizer Investigational Site Bethesda Maryland 20817
Pfizer Investigational Site Ann Arbor Michigan 48106
Pfizer Investigational Site Troy Michigan 48085
Pfizer Investigational Site Columbus Mississippi 39705
Pfizer Investigational Site Corinth Mississippi 38834
Pfizer Investigational Site Tupelo Mississippi 38801
Pfizer Investigational Site City of Saint Peters Missouri 63376
Pfizer Investigational Site St Louis Missouri 63110
Pfizer Investigational Site Omaha Nebraska 68105
Pfizer Investigational Site Las Vegas Nevada 89102
Pfizer Investigational Site Las Vegas Nevada 89106
Pfizer Investigational Site Jamaica New York 11432
Pfizer Investigational Site Norman Oklahoma 73071
Pfizer Investigational Site Oklahoma City Oklahoma 73102
Pfizer Investigational Site Oklahoma City Oklahoma 73109
Pfizer Investigational Site Oklahoma City Oklahoma 73120
Pfizer Investigational Site Tulsa Oklahoma 74014
Pfizer Investigational Site Tulsa Oklahoma 74104
Pfizer Investigational Site Tulsa Oklahoma 74136
Pfizer Investigational Site Lancaster Pennsylvania 17605
Pfizer Investigational Site Knoxville Tennessee 37920
Pfizer Investigational Site Beaumont Texas 77701
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Grapevine Texas 76051
Pfizer Investigational Site Irving Texas 75063
Pfizer Investigational Site Bountiful Utah 84010
Pfizer Investigational Site Layton Utah 84041
Pfizer Investigational Site Murray Utah 84157
Pfizer Investigational Site Provo Utah 84604
Pfizer Investigational Site Salt Lake City Utah 84102
Pfizer Investigational Site Salt Lake City Utah 84106
Pfizer Investigational Site Sandy City Utah 84094
Pfizer Investigational Site West Valley City Utah 84102
Pfizer Investigational Site Kennewick Washington 99336

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00457392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2013 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00457392 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →